Analysis of sphingolipid composition in human vitreous from control and diabetic individuals

Lynda A. Wilmott, Richard C. Grambergs, Jeremy C. Allegood, Timothy J. Lyons, Nawajes Mandal

Research output: Contribution to journalArticle

Abstract

Objective: Sphingolipids have a fundamental role in many cellular processes, and they have been implicated in insulin resistance and Diabetes Mellitus (DM) and its complications, including diabetic retinopathy (DR). Little is known about how bioactive sphingolipids relate to retinopathies in human DM. In this study, we analyzed the sphingolipid composition of type 2 diabetic (T2DM) and non-diabetic human vitreous samples. Methods: We conducted an observational study on post-mortem human vitreous samples from non-diabetic (Controls; n = 4; age: 71.6 ± 11.0 years, mean ± SD) and type 2 diabetic (T2DM; n = 9; age: 67.0 ± 9.2 years) donors to identify changes in sphingolipid composition. Samples were analyzed by a triple quadrupole mass spectrometer and individual sphingolipid species were identified and quantified using established protocols. Results: The total quantity (pmol/mg) of ceramide (Cer), lactosylceramide (Lac-Cer), and sphingomyelin (SM) were increased in type 2 diabetic vitreous samples. Among individual species, we found a general trend of increase in the longer chain species of ceramides, hexosylceramides (Hex-Cer), Lac-Cer, and SM. Conclusions: This study shows the presence of measurable levels of sphingolipids in human vitreous. The results indicate changes in sphingolipid composition in the vitreous due to type 2 diabetes, which could be connected to the disease pathologies of the retina, retinal vessels, vitreous and the surrounding tissues.

Original languageEnglish (US)
Pages (from-to)195-201
Number of pages7
JournalJournal of Diabetes and its Complications
Volume33
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Sphingolipids
Sphingomyelins
Ceramides
Retinal Vessels
Diabetic Retinopathy
Diabetes Complications
Type 2 Diabetes Mellitus
Observational Studies
Insulin Resistance
Retina
Diabetes Mellitus
Pathology

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Analysis of sphingolipid composition in human vitreous from control and diabetic individuals. / Wilmott, Lynda A.; Grambergs, Richard C.; Allegood, Jeremy C.; Lyons, Timothy J.; Mandal, Nawajes.

In: Journal of Diabetes and its Complications, Vol. 33, No. 3, 01.03.2019, p. 195-201.

Research output: Contribution to journalArticle

Wilmott, Lynda A. ; Grambergs, Richard C. ; Allegood, Jeremy C. ; Lyons, Timothy J. ; Mandal, Nawajes. / Analysis of sphingolipid composition in human vitreous from control and diabetic individuals. In: Journal of Diabetes and its Complications. 2019 ; Vol. 33, No. 3. pp. 195-201.
@article{43b76b9a95454d06b7eb7e0da6fccfd9,
title = "Analysis of sphingolipid composition in human vitreous from control and diabetic individuals",
abstract = "Objective: Sphingolipids have a fundamental role in many cellular processes, and they have been implicated in insulin resistance and Diabetes Mellitus (DM) and its complications, including diabetic retinopathy (DR). Little is known about how bioactive sphingolipids relate to retinopathies in human DM. In this study, we analyzed the sphingolipid composition of type 2 diabetic (T2DM) and non-diabetic human vitreous samples. Methods: We conducted an observational study on post-mortem human vitreous samples from non-diabetic (Controls; n = 4; age: 71.6 ± 11.0 years, mean ± SD) and type 2 diabetic (T2DM; n = 9; age: 67.0 ± 9.2 years) donors to identify changes in sphingolipid composition. Samples were analyzed by a triple quadrupole mass spectrometer and individual sphingolipid species were identified and quantified using established protocols. Results: The total quantity (pmol/mg) of ceramide (Cer), lactosylceramide (Lac-Cer), and sphingomyelin (SM) were increased in type 2 diabetic vitreous samples. Among individual species, we found a general trend of increase in the longer chain species of ceramides, hexosylceramides (Hex-Cer), Lac-Cer, and SM. Conclusions: This study shows the presence of measurable levels of sphingolipids in human vitreous. The results indicate changes in sphingolipid composition in the vitreous due to type 2 diabetes, which could be connected to the disease pathologies of the retina, retinal vessels, vitreous and the surrounding tissues.",
author = "Wilmott, {Lynda A.} and Grambergs, {Richard C.} and Allegood, {Jeremy C.} and Lyons, {Timothy J.} and Nawajes Mandal",
year = "2019",
month = "3",
day = "1",
doi = "10.1016/j.jdiacomp.2018.12.005",
language = "English (US)",
volume = "33",
pages = "195--201",
journal = "Journal of Diabetes and its Complications",
issn = "1056-8727",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Analysis of sphingolipid composition in human vitreous from control and diabetic individuals

AU - Wilmott, Lynda A.

AU - Grambergs, Richard C.

AU - Allegood, Jeremy C.

AU - Lyons, Timothy J.

AU - Mandal, Nawajes

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Objective: Sphingolipids have a fundamental role in many cellular processes, and they have been implicated in insulin resistance and Diabetes Mellitus (DM) and its complications, including diabetic retinopathy (DR). Little is known about how bioactive sphingolipids relate to retinopathies in human DM. In this study, we analyzed the sphingolipid composition of type 2 diabetic (T2DM) and non-diabetic human vitreous samples. Methods: We conducted an observational study on post-mortem human vitreous samples from non-diabetic (Controls; n = 4; age: 71.6 ± 11.0 years, mean ± SD) and type 2 diabetic (T2DM; n = 9; age: 67.0 ± 9.2 years) donors to identify changes in sphingolipid composition. Samples were analyzed by a triple quadrupole mass spectrometer and individual sphingolipid species were identified and quantified using established protocols. Results: The total quantity (pmol/mg) of ceramide (Cer), lactosylceramide (Lac-Cer), and sphingomyelin (SM) were increased in type 2 diabetic vitreous samples. Among individual species, we found a general trend of increase in the longer chain species of ceramides, hexosylceramides (Hex-Cer), Lac-Cer, and SM. Conclusions: This study shows the presence of measurable levels of sphingolipids in human vitreous. The results indicate changes in sphingolipid composition in the vitreous due to type 2 diabetes, which could be connected to the disease pathologies of the retina, retinal vessels, vitreous and the surrounding tissues.

AB - Objective: Sphingolipids have a fundamental role in many cellular processes, and they have been implicated in insulin resistance and Diabetes Mellitus (DM) and its complications, including diabetic retinopathy (DR). Little is known about how bioactive sphingolipids relate to retinopathies in human DM. In this study, we analyzed the sphingolipid composition of type 2 diabetic (T2DM) and non-diabetic human vitreous samples. Methods: We conducted an observational study on post-mortem human vitreous samples from non-diabetic (Controls; n = 4; age: 71.6 ± 11.0 years, mean ± SD) and type 2 diabetic (T2DM; n = 9; age: 67.0 ± 9.2 years) donors to identify changes in sphingolipid composition. Samples were analyzed by a triple quadrupole mass spectrometer and individual sphingolipid species were identified and quantified using established protocols. Results: The total quantity (pmol/mg) of ceramide (Cer), lactosylceramide (Lac-Cer), and sphingomyelin (SM) were increased in type 2 diabetic vitreous samples. Among individual species, we found a general trend of increase in the longer chain species of ceramides, hexosylceramides (Hex-Cer), Lac-Cer, and SM. Conclusions: This study shows the presence of measurable levels of sphingolipids in human vitreous. The results indicate changes in sphingolipid composition in the vitreous due to type 2 diabetes, which could be connected to the disease pathologies of the retina, retinal vessels, vitreous and the surrounding tissues.

UR - http://www.scopus.com/inward/record.url?scp=85059507400&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059507400&partnerID=8YFLogxK

U2 - 10.1016/j.jdiacomp.2018.12.005

DO - 10.1016/j.jdiacomp.2018.12.005

M3 - Article

VL - 33

SP - 195

EP - 201

JO - Journal of Diabetes and its Complications

JF - Journal of Diabetes and its Complications

SN - 1056-8727

IS - 3

ER -